Distinct chemokine receptor and cytokine expression profile in secondary progressive MS

Neurology

Volumn 57, Issue 8, 2001, Pages 1371-1376

  Sørensen, Torben L ^a   Sellebjerg, Finn ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR; CHEMOKINE RECEPTOR CCR2; CHEMOKINE RECEPTOR CCR3; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR3; CYTOKINE; INTERFERON BETA SERINE; INTERLEUKIN 5; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; CLINICAL ARTICLE; DISEASE COURSE; DRUG EFFECT; DRUG MECHANISM; FEMALE; FLOW CYTOMETRY; HUMAN; MALE; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; REGULATORY MECHANISM; RELAPSE; T LYMPHOCYTE; TH2 CELL; TREATMENT OUTCOME;

EID: 18544404188     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.57.8.1371     Document Type: Article

References (40)

1. Multiple sclerosis
2. Heterogeneity of multiple sclerosis lesions: Implications for the pathogenesis of demyelination
3. Axonal transection in the lesions of multiple sclerosis
4. Acute axonal injury in multiple sclerosis. Correlation with demyelination and inflammation
5. Axonal pathology in multiple sclerosis: Relationship to neurological disability
6. Interferon β-lb in the treatment of multiple sclerosis: Final outcome of the randomized controlled trial
7. Randomized double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis
8. European Study Group on interferon beta-1b in secondary progressive MS. Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis
9. MRI dynamics of brain and spinal cord in progressive multiple sclerosis
10. Elevated serum interleukin-2 levels in chronic progressive multiple sclerosis
11. Association between tumor necrosis factor-alpha and disease progression in patients with multiple sclerosis
12. Increased interleukin 12 production in progressive multiple sclerosis: Induction by activated CD4+ T cell via CD40 ligand
13. Chemokines-chemotactic cytokines that mediate inflammation
14. Chemokines. A new classification system and their role in immunity
15. Mechanisms of inflammation in MS tissue: Adhesion molecules and chemokines
16. Chemokines and chemokine receptors in inflammation of the nervous system: Manifold roles and exquisite regulation
17. Expression of specific chemokines and chemokine receptors in the central nervous system of multiple sclerosis patients
18. CCR5+ and CXCR3+ T cells are increased in multiple sclerosis and their ligands MIP-1alfa and IP-10 are expressed in demyelinating brain lesions
19. MIP-1alpha and MCP-1 differentially regulate acute and relapsing autoimmune encephalomyelitis as well as Th1/Th2 lymphocyte differentiation
20. Rating neurological impairment in multiple sclerosis: An expanded disability status scale (EDSS)
21. Differential CC chemokine-induced enhancement of T helper cell cytokine production
22. Control of Th2 polarization by the chemokine monocyte chemoattractant protein-1
23. CCR5 is characteristic of Th1 lymphocytes
24. Monocyte chemoattractant protein 1 acts as a T-lymphocyte chemoattractant
25. Cutting edge commentary. Chemokine regulation of experimental autoimmune encephalomyelitis: Temporal and spatial expression patterns govern disease pathogenesis
26. Resistance to experimental autoimmune encephalomyelitis in mice lacking the CC chemokine receptor (CCR)2
27. CC chemokine receptor 2 is critical for induction of experimental autoimmune encephalomyelitis
28. MCP-1, MCP-2 and MCP-3 expression in multiple sclerosis lesions: An immunohistochemical and in situ hybridization study
29. Expression of monocyte chemoattractant protein-1 and other betachemokines by resident and inflammatory cells in multiple sclerosis lesions
30. Localization of monocyte chemoattractant peptide-1 expression in the central nervous system in experimental autoimmune encephalomyelitis and trauma in the rat
31. The chemokine monocyte chemoattractant protein-1 (MCP-1) is expressed by astrocytes after mechanical injury to the brain
32. CCR5 41 32, matrix metalloproteinase-9, and disease activity in multiple sclerosis
33. Chronic exposure to tumor necrosis factor (TNF) in vitro impairs the activation of T cells through the T cell receptor/CD3 complex; reversal in vivo by anti-TNF antibodies in patients with rheumatoid arthritis
34. Less mortality but more relapses in experimental allergic encephalomyelitis in CD8-A/- mice
35. The application of multifactorial cluster analysis in the staging of plaques in early multiple sclerosis
36. Acute axonal injury in multiple sclerosis. Correlation with demyelination and inflammation
37. Inhibition of T cell responses by activated human CD8+ T cells is mediated by interferon-gamma and is defective in chronic progressive multiple sclerosis
38. Induction or protection from experimental autoimmune encephalomyelitis depends on the cytokine secretion profile of TCR peptide-specific regulatory CD4 T cells
39. Differential expression of chemokine receptors and chemotactive responsiveness of type 1 T helper cells (Th1s) and Th2s
40. The chemokine receptors CXCR3 and CCR5 mark subsets of T cells associated with certain inflammatory reactions